**Newer Anti Epileptic Drug :Levetiracetam**

 Levetiracetam (LEV) is a new Antiepileptic Drug (AED) having unique pharmacologic and metabolic properties .[1] Levetiracetam does not interact with commonly used drugs and other antiepileptic Drugs (AED).[2] It has a favourable safety profile and the most frequently reported adverse events were somnolence, asthenia and dizziness along side nasopharyngitis,diarrhea constipation and even Steven Johnson Syndrome Lyell syndrome liver failure and hepatitis[3] . Overall, Levetiracetam is considered to have several advantages with least adverse effects over the current antiepileptic drug.The major advantage of Levetiracetam is its easy administration and lack of drug to drug interactions. [4]

 It is considered as novel anti epileptic drugs with broad-spectrum of anticonvulsunt activity with unusually high safety margina and considered as promising alternative to VPA (Valporic acid )for many patients .It was introduced in the Indian market as a new Antiepileptic Drug 2005.Basically it was synthesized in 1980 through follow up of chemical program for identifying 2nd generation nootropic agents .[5] Its chemical name is S- alpha ethyl-2-oxo-1pyrrolidine acetamide with molecular formula C8H14N2O2 with a molecular weight of 170.21. [6]

 **Mechanism of Action**

 Levetiracetam is said to be have highly specific brain-binding site 120. Levetiracetam selectively binds to synaptic vesicle glycoprotein 2A(SV2A) in presynaptic terminals throughout brain SV2A interacts with Calcium sensor synaptotagmin through its N terminal (cytosolic) domain These synaptic vesicles (SVs) are a specialized class of tiny (40–50 nmdiameter) secretory vesicles localized in presynaptic nerve terminals.SVs have two major functions: the accumulation and storage of neurotransmitters and the release of these neuro-transmitters[8].

 When an action potential arrives at a nerve terminal, it causes an influx of calcium (Ca 2+ ) through voltage-gated Ca 2+ channels, which triggers the vesicles to release their contents within a fraction of a millisecond [9]. The neurotransmitters are secreted in multi-molecular packets, each containing several thousand neuro- transmitter molecules. At rest, nerve terminals release neuro-transmitter molecules spontaneously at a slow rate, giving rise to spontaneous miniature synaptic potentials[10] .SVs are released and reused in a simple but well-balanced cycle of exocytosis and endocytosis, its *yin* and *yang* elements [11]. The exocytosis process begins once the SVs are filled with neurotransmitters by active transport and are conveyed close to the active zone of the presynaptic plasma membrane, where they reside in a cluster ready to be recruited for exocytosis[12,13].

 Vesicle clusters appear to be homogeneous, with little sign of any morphological boundary that might demarcate the functional pools [14]. Biochemists have isolated many of the key proteins of SVs. These proteins fall into two major classes: transport proteins involved in neurotransmitter uptake and trafficking proteins that participate in synaptic vesicle exocytosis, endocytosis, and recycling.[15] The SV2A is expressed ubiquitously throughout the brain at different levels, with the exception of the facial and trigeminal nuclei[16]

 As expected for a synaptic vesicle protein, SV2A is essentially absent in the neuronal soma[16]. Both in humans and in rats, SV2A immunoreactivity (IR) is present in synaptic layers throughout all subfields of the hippocampal formation. The strongest IR is observed in the stratum lucidum of CA3 (mossy fibers) and in the hilar region of the dentate gyrus (DG). Because SV2A is a protein localized in the terminal pre-synaptic axons of neurons, its expression is observed surrounding the dendrites or somata of the postsynaptic pyramidal neurons (CA1 and CA3), granular cells, and hilar cells[17,18].

 SV2A is expressed in both glutamatergic and GABAergic terminals ; immune-cytochemical studies in the rat cortex, hippocampus, and cerebellum showed that SV2A co-localizes with vesicular glutamate transporters ( VGLUT ) 1 and 2 and with the vesicular γ -aminobutyric acid (GABA) transporter (VGAT).[16,18,19]]. Intriguingly, SV2A is mostly co-expressed with VGLUT1 and VGAT (82 % and 96 %, respectively) and less so VGLUT2 (42 %); however, the distribution is almost equal among all terminals [19].

 The localization of SV2A in all SVs, together with its conservation across species, suggests that the protein is highly important in vesicle functioning [20]. Although it is well known that SV2A is not indispensable for neurotransmitter release, its function is clearly essential to normal neurotransmitter release for at least the more complex vertebrate nervous systems [21,22]. Its function remains undefined, but most evidence suggests that SV2A potentially has multiple regulatory actions at diverse points in the synaptic vesicle cycle [21,22,23]

 Levetiracetam has also role in modulation of presynaptic P/Q type voltage dependant calcium channels to reduce glutamate release and inhibition in dendate gyrus which may be contributing factor anti epileptic action of levetiracetam.[24]

 It is well evident that Levetiracetam selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons,suggesting the existence of a subtype of N-type channels sensitive to LEV,which might be involved in the molecular basis of its antiepileptic action of LEV.[25] Further it has been shown that LEV may,at least partly, mediate some of its antiepileptic effects via preventing this Zn modulation of presynaptic GABAA receptors as a antiepilectic agent.[26]

Levetiracetam has shown the effect of hyperalgesia which is at least in part mediated by GABA, opioid, 5-HT and a2-adrenergic receptors. Beside this levetiracetam has a non specific action on opioid, 5-HT receptor , which may be be cause for side nausea, vomiting like side effects .[26]

 **Pharmacokinetics of Levetiracetam: Absorption and Distribution** Levetiracetam is rapidly and almost completely (*>*95%) absorbed following oral ingestion with Tmax occurring at 1.3–5.2 h. [28] The mean half-life (t1*/*2) of LEV in serum is 6–13.3 h 126,132. Levetiracetam easily enters the cerebrospinal fluid (CSF) compartment with a Tmax of 3–7.3 h[28,29]

 The mean t1*/*2 of Levetiracetam in CSF is 24 h, showing that the efflux of Levetiracetam from the CNS compartment is twice as long as that from the blood [29]. LEV seems to have a prolonged duration of action, supporting a twice-daily dosing strategy [28].That is why Levetiracetam can be started with full dose (500 mg daily) prior need of any drug titration unlike other anti epileptic drugs. Its major route of elimination is renal and its twice daily dosing is established in early pharmacodynamic and phase - controlled studies.[7]

 N-pyrrolidine butyric acid {PBA} is the major metabolite of Levetiracetam .The fraction of Levetiracetam metabolized to PBA is 2-4 %in case of mice and 2-5 % in the case of dog, but in the case of human it is 26 % .[5,7] PBA as a major metabolite of Levetiracetam structurally resembles Valporic acid analogue (VPA) except for the presence of a pyrrolidine ring instead of aliphatic chain at the second carbon atom .[1]

 Unlike other epileptic drugs , Levetiracetam is extremely water soluble so this allows rapid and complete absorption after oral administration . Levetiracetam is not metabolized by liver (not involving the hepatic cytochrome P450 [CYP] system)[28]  and hence free of non linear elimination kinetics and free of major drug-drug interactions and further Lack of protein binding also avoids problems of displacing highly protein –bound drugs [7]

 reference –issorehanet al [31]

**Figure no -2: showing chemical representation of levetricetam**
 and its overall, no significant differences in pharmacokinetics between sexes or races have been reported, although some special populations require extra care[32] as such dosage of Levetiracetam should be adjusted for some special populations. In children, renal clearance is higher and dosage should be increased to approximately 130% of the adult dose on a per kg of body weight basis [28,34,35].

 Elderly people often show a reduction in renal clearance and dosage should be lowered accordingly. Likewise, in patients showing renal impairment or suffering from hepatorenal syndrome, dosage reduction should be considered[33]. Pregnant women undergo a variety of physiological changes including increased hepatic metabolism, decreased plasma protein binding, and fluctuating hormone levels.Renal functioning increases during pregnancy, meaning that plasma concentrations of drugs that are excreted by kidneys, like Levetiracetam, could decrease, and dose adjustment may be required.[33,35]

 **Dosage and Administration of Levetiracetam**

 It is available in markets as film-coated tablets containing 250, 500, 750, and 1000 mg  [36]. Levetiracetam can be administer without regard to meal times: The time at which peak concentrations occur in serum is delayed slightly but the maximum concentration (Cmax) is unaffected by food intake[28,36]. For epilepsy patients recommended dose of Levetiracetam (1000 mg/day) can be titrated uo to 2000 mg/day or 3000 mg/day to provide seizure free state with little or no increased risk for adverse events. Levetiracetam treatment is usually started at 500 mg twice daily and increased in two-weekly steps of 1000 mg/day to 3000 mg/day[36].

 Reports indicate that the target range for daily dosage of 1000–3000 mg is 35–120 *μ*mol/L to achieve serum concentration in patients[28].

 Levetiracetam is well tolerated up to a dosage of 4000 mg/day, with increased incidence of somnolence and asthenia. Hence dose escalation above 3000 mg/day should be done only after careful analyses of the risk–benefit ratio, due to a higher risk for adverse effects apparent from several studies[37].

 A liquid formulation ( 100 mg/mL) for oral ingestion has been developed for those patients with difficulties in swallowing. In 2006, an intravenous (i.v.) Levetiracetam formulation was approved for use as adjunctive therapy in the treatment of epilepsy by both the Food and Drug Administration (FDA) and the European Agency for Evaluation of Medicinal products (EMEA).

 Levetiracetam administered by i.v. infusion is indicated in emergency situations and appears to be well tolerated in healthy subjects, with a pharmacokinetic profile 129,130. The intravenous formulation is provided in 5-mL glass vials containing 500 mg Levetiracetam (Levetiracetam 100 mg/mL), which should be infused over 15 minutes.

1. A**dverse effects of Levetiracetam .**

 It is seen that Levetiracetam is reported for resulting in rhabdomyolysis,158 myoclonic encephalopathy in renal failure patients[38] , Levetiracetam induced rage and suicidability ,[39] and acute psychosis [40],severe acute glomerulonephritis[41]

**Name of Author :- Dr Nilesh K Jaybhaye
 MBBS, MD (Anatomy)
 NEIGRIHMS, Shillong , Meghalaya

Email:-** **pawanwagh0001140@gmail.com** **References :**Marineanu D G,Klitgaard H:Levetiracetam Mechanism of action :*Antiepileptic Drugs 5th edition 2002 :419-427*
2. Singh D P,Soni N K :The New Antiepileptic Drugs:*Agarwal A K ed,Medicine update Proceedings of scientific Sessions APICON 2009 :A Publication of Association of Physicians of India ,Greater Noida Delhi*
3. Wilson, J. G: Present status of drugs as teratogens in man:*Teratology :1973:vol-7 (1):3–15*
4. Kewal K Jain :An assessment of levetiracetam as an anti-epileptic drug;Abstract Drug Evaluation :July 2000, Vol. 9, (7 );1611-1624
5. Nau H,Hauck R-S, Ehlers K: Valporic acid-induced neural tube defects in mouse & human :aspect of chirality,alternative drug development,pharmacokinetics & possible mechanism: *Pharmacol Toxicol 1991:69; 310-321*
6. Milind J Kothari ,Carl W Bazil:Update on Antiseizure Drugs *Neurology Board review Manual: Volume 6- part 2:1-15*
7. Isoherranen N,Ygen B ,Roeder M, et al:Pharmacokinetics of Levetiracetam & its Enantiomer(R)-alpha-2-oxo-pyrrolidine acetamide in Dogs:*Epelipsia 2000:42;825-830*
8. McAuley JW, Anderson GD (2002) Treatment of epilepsy in women of reproductive age: Pharmacokinetic considerations. *Clin Pharmacokinet 41*:559-579.
9. Sudhof TC (1989) Synaptic vesicles. Curr Opin Cell Biol :1989 :1(4):655–659
10. Alberts B, Johnson A, Lewis J et al (2002) Intracellular vesicular traffi c. In*: Alberts B, Johnson A, Lewis J (eds) Molecular biologyof the cell, 4th edn. Garland Science, New York, NY, pp 749–812*
11. Nicholls JG, Martin A, Fuchs PA, Brown DA, Diamond ME, Weisblat DA :Release of neurotransmitters. In: *Nicholls JG, Martin AR, Fuchs PA, Brown DA, Diamond ME,Weisblat DA (eds) From neuron to brain, 5th edn. Sinauer Associates, Inc, Sunderland,MA,2012 p 241, 264–271*
12. Zhang B, Ramaswami M (1999) Synaptic vesicle endocytosis and recycling. In: *BellenHJ: Neurotransmitter release. Oxford University Press, Oxford, p 389*
13. Siegelbaum SA, Kandel ER, Südhof TC :Transmitter release. In: *Kandel ER,Schwartz JH, Jessell TM, Siegelbaum SA,Hudspeth AJ (eds) Principles of neural science,5th edn 2013: Mc Graw Hill, New York, NY,pp 275–287*
14. Sudhof TC : The molecular machinery of neurotransmitter release (Nobel lecture).Angew Chem Int Ed Engl :2014;(47):12696–12717
15. Richards DA, Guatimosim C, Betz WJ:Two endocytic recycling routes selectively fill two vesicle pools in frog motor nerve terminals.Neuron :2000:27(3):551–559
16. Sudhof TC:The synaptic vesicle cycle.Annu Rev Neurosci :2004: 27:509–547.
17. Bajjalieh SM, Frantz GD, Weimann JM,McConnell SK, Scheller RH ;Differential expression of synaptic vesicle protein 2 (SV2) isoforms:*J Neurosci:1994:14(9):5223–5235*
18. .Van Vliet EA, Aronica E, Redeker S, Boer K,Gorter JA :Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy:*Epilepsia :2009: 50(3):422–433.*
19. Ohno Y, Ishihara S, Terada R, Kikuta M,Sofue N, Kawai Y, Serikawa T, Sasa M:Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole Kindling: *Biochem Biophys Res Commun :2009:390(3):415–420.*
20. Bajjalieh SM, Peterson K, Shinghal R, SchellerRH: SV2, a brain synaptic vesicle protein homologous to bacterial transporters; *Science:1992: 257(5074):1271–1273*
21. Janz R, Goda Y, Geppert M, Missler M,Sudhof TC (1999) SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitterrelease:*Neuron ;1999:24(4):1003–1016*
22. Nowack A, Yao J, Custer KL, Bajjalieh SM(2010) SV2 regulates neurotransmitter release via multiple mechanisms*:Am J Physiol Cell Physiol ;2010:299(5):C960–C967.*
23. Yao J, Nowack A, Kensel-Hammes P, Gardner RG, Bajjalieh SM:Cotrafficking of SV2 and synaptotagmin at the synapse:*J Neurosci:2010:30(16):5569–5578*.
24. Xu T, Bajjalieh SM:SV2 modulates the size of the readily releasable pool of secretory vesicles:*Nat Cell Biol:2001:3(8):691–698.*
25. Chun-Yao Lee, Chih-Chuan Chen and Horng-Huei Liou:Levetiracetam inhibits glutamate transmission through presynaptic P/Q type channels on the granule cells of the dentate gyrus :*British journal of Pharmacology :2009:158;1753-1762*
26. Lukyanetz EA, et al: Selective blockade of N-type calcium channels by Levetiracetam:*Epilepsia:2002*.
27. Masahito Wakita, Naoki Kotani, Kyuya Kogure, and Norio Akaike: Inhibition of Excitatory Synaptic Transmission in Hippocampal Neurons by Levetiracetam Involves Zn21-Dependent GABA Type A Receptor–Mediated Presynaptic Modulation: *The Journal of Pharmacology and Eperimental Therapeutics: 2014: 348:246–259,*
28. A Micov, M Tomic, B Popovic and R Stepanovic,Petrovic: The antihyperalgesic effect of levetiracetam in an inflammatory model of pain in rats: mechanism of action:*British Journal of Pharmacology ;2010:1476-5381*
29. Patsalos PN. (2000) Pharmacokinetic profile of levetiracetam: Toward ideal characteristics. *Pharmacol Ther 85*:77-85
30. Edwards KR, Glantz MJ, Bator T, Button J (2004) Levetiracetam levels in human cerebrospinal fluid:Acontrolled, dose ranging pharmacokinetic study. *Neurology 62*:118
31. Orakwue A. Molokwu ⁎, Birinus A. Ezeala-Adikaibe, Ikenna O. Onwuekwe: Levetiracetam-induced rage and suicidality: Two case reports and review of literature*: Epilepsy & Behavior Case Reports :2015:4: 79–81*
32. Surijita Dutta :Human Teratogens and Their Effects:A Critical Evaluation :*International Journal of Information Research and Review:Vol-2:Issue 3:525-536*
33. French J (2001) Use of levetiracetam in special populations. *Epilepsia 42*:40-43.
34. Pellock JM, Glauser TA, Bebin EM, Fountain NB, Ritter FJ, Coupez RM, Shields WD (2001) Pharmacokinetic study of levetiracetam in children. *Epilepsia 42*:1574-1579.
35. McAuley JW, Anderson GD (2002) Treatment of epilepsy in women of reproductive age: Pharmacokinetic considerations. *Clin Pharmacokinet 41*:559-579.
36. Patsalos PN (2004) Clinical pharmacokinetics of levetiracetam. *Clin Pharmacokinet 43*:707-724.
37. Ramael S, De Smedt F, Toublanc N, Otoul C, Boulanger P, Riethuisen JM, Stockis A (2006b) Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. *Clin Ther 28*:734-744.
38. [Vaibhav Rastogi](https://www.ncbi.nlm.nih.gov/pubmed/?term=Rastogi%20V%5BAuthor%5D&cauthor=true&cauthor_uid=30062079), [Devina Singh](https://www.ncbi.nlm.nih.gov/pubmed/?term=Singh%20D%5BAuthor%5D&cauthor=true&cauthor_uid=30062079),[Babbaljeet Kaur](https://www.ncbi.nlm.nih.gov/pubmed/?term=Kaur%20B%5BAuthor%5D&cauthor=true&cauthor_uid=30062079),[Pulkit Arora](https://www.ncbi.nlm.nih.gov/pubmed/?term=Arora%20P%5BAuthor%5D&cauthor=true&cauthor_uid=30062079),and [Jaya P Gadikota](https://www.ncbi.nlm.nih.gov/pubmed/?term=Gadikota%20JP%5BAuthor%5D&cauthor=true&cauthor_uid=30062079)Rhabdomyolysis: A Rare Adverse Effect of Levetiracetam: [*Cureus*](https://www.ncbi.nlm.nih.gov/pmc/journals/2757/)*:2018:10(5); 2705*
39. Orakwue A. Molokwu ⁎, Birinus A. Ezeala-Adikaibe, Ikenna O. Onwuekwe: Levetiracetam-induced rage and suicidality: Two case reports and review of literature*: Epilepsy & Behavior Case Reports :2015:4: 79–81*
40. Syed Ahmed Zaki, Saurabh Gupta :Levetiracetam-induced acute psychosis in a child:*Indian Journal of Pharmacology 2014 :46(3): 341-342*
41. Katrina Chau, Jim Yong, Kasim Ismail, Neil Griffith, Michael Liu4 and Angela Makris:Levetiracetam-induced severe acute granulomatous interstitial nephritis:*Clin Kidney J :2012:5: 234–236*